{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T12:41:13Z","timestamp":1773751273671,"version":"3.50.1"},"reference-count":32,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2009,11,1]],"date-time":"2009-11-01T00:00:00Z","timestamp":1257033600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2009,11]]},"DOI":"10.1016\/j.intimp.2009.08.008","type":"journal-article","created":{"date-parts":[[2009,8,24]],"date-time":"2009-08-24T08:08:35Z","timestamp":1251101315000},"page":"1381-1386","source":"Crossref","is-referenced-by-count":21,"title":["Naloxone can improve the anti-tumor immunity by reducing the CD4+CD25+Foxp3+ regulatory T cells in BALB\/c mice"],"prefix":"10.1016","volume":"9","author":[{"given":"Agheel Tabar","family":"Molla Hassan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zuhair M.","family":"Hassan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seyed Mohammad","family":"Moazzeni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ali","family":"Mostafaie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shahram","family":"Shahabi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Massoumeh","family":"Ebtekar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seyed Mahmoud","family":"Hashemi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.intimp.2009.08.008_bib1","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1126\/science.278.5335.117","article-title":"Immunotherapy of tumors with autologous tumor-derived heat shock protein preparations","volume":"278","author":"Tamura","year":"1997","journal-title":"Science"},{"key":"10.1016\/j.intimp.2009.08.008_bib2","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1379\/1466-1268(2000)005<0462:THSPGA>2.0.CO;2","article-title":"The heat shock protein gp96: a receptor-targeted cross-priming carrier and activator of dendritic cells","volume":"5","author":"Singh-Jasuja","year":"2000","journal-title":"Cell Stress Chaperones"},{"key":"10.1016\/j.intimp.2009.08.008_bib3","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1007\/s00262-005-0662-9","article-title":"Dendritic cells pulsed with gp96-peptide complexes derived from human hepatocellular carcinoma (HCC) induce specific cytotoxic T lymphocytes","volume":"54","author":"Wang","year":"2005","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.intimp.2009.08.008_bib4","doi-asserted-by":"crossref","first-page":"7254","DOI":"10.4049\/jimmunol.179.11.7254","article-title":"Specific immunogenicity of heat shock protein gp96 derives from chaperoned antigenic peptides and not from contaminating proteins","volume":"179","author":"Binder","year":"2007","journal-title":"J Immunol"},{"key":"10.1016\/j.intimp.2009.08.008_bib5","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/S1074-7613(01)00111-X","article-title":"CD91 is a common receptor for heat shock proteins gp96, hsp90, hsp70, and calreticulin","volume":"14","author":"Basu","year":"2001","journal-title":"Immunity"},{"key":"10.1016\/j.intimp.2009.08.008_bib6","doi-asserted-by":"crossref","first-page":"3362","DOI":"10.1016\/j.vaccine.2008.03.082","article-title":"Enhanced immunogenicity of HPV16E7 accompanied by Gp96 as an adjuvant in two vaccination strategies","volume":"26","author":"Bolhassani","year":"2008","journal-title":"Vaccine"},{"key":"10.1016\/j.intimp.2009.08.008_bib7","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.coi.2007.02.004","article-title":"Regulatory T cells and cancer","volume":"19","author":"Wang","year":"2007","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.intimp.2009.08.008_bib8","doi-asserted-by":"crossref","first-page":"3331","DOI":"10.1016\/j.vaccine.2009.01.084","article-title":"Mechanism of action of licensed vaccine adjuvants","volume":"27","author":"Tritto","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.intimp.2009.08.008_bib9","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1007\/s11481-006-9026-2","article-title":"Opioid receptors and signaling on cells from the immune system","volume":"1","author":"Bidlack","year":"2006","journal-title":"J Neuroimmune Pharmacol"},{"key":"10.1016\/j.intimp.2009.08.008_bib10","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.bbi.2007.06.009","article-title":"Neuroimmune mechanisms of opioid-mediated conditioned immunomodulation","volume":"22","author":"Saurer","year":"2008","journal-title":"Brain Behav Immun"},{"key":"10.1016\/j.intimp.2009.08.008_bib11","doi-asserted-by":"crossref","first-page":"683","DOI":"10.2174\/092986608785133591","article-title":"Opioid peptides and innate immune response in mollusc","volume":"15","author":"Liu","year":"2008","journal-title":"Prot Peptide Letters"},{"key":"10.1016\/j.intimp.2009.08.008_bib12","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1093\/intimm\/dxn139","article-title":"A novel adjuvant, the general opioid antagonist naloxone, elicits a robust cellular immune response for a DNA vaccine","volume":"21","author":"Jamali","year":"2009","journal-title":"Int Immunol"},{"key":"10.1016\/j.intimp.2009.08.008_bib13","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1055\/s-2007-972959","article-title":"Effects of naloxone opiate blockade on the immunomodulation induced by exercise in rats","volume":"16","author":"Bouix","year":"1995","journal-title":"Int J Sports Med"},{"key":"10.1016\/j.intimp.2009.08.008_bib14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1081\/IPH-100102562","article-title":"In vitro effects of naloxone on T-lymphocyte-dependent antibacterial activity in hepatitis C virus (HCV) infected patients and in inflammatory bowel disease (IBD) patients","volume":"23","author":"Amati","year":"2001","journal-title":"Immunopharmacol Immunotoxicol"},{"key":"10.1016\/j.intimp.2009.08.008_bib15","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1111\/j.1749-6632.2000.tb05440.x","article-title":"The opioid antagonist naloxone induces a shift from type 2 to type 1 cytokine pattern in normal and skin-grafted mice","volume":"917","author":"Sacerdote","year":"2000","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.intimp.2009.08.008_bib16","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1182\/blood.V95.6.2031","article-title":"The opioid antagonist naloxone induces a shift from type 2 to type 1 cytokine pattern in BALB\/cJ mice","volume":"95","author":"Sacerdote","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.intimp.2009.08.008_bib17","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1097\/00004630-198911000-00006","article-title":"Naloxone inhibits the in vivo immunosuppressive effects of morphine and thermal injury in mice","volume":"10","author":"Hendrickson","year":"1989","journal-title":"J Burn Care Rehabil"},{"key":"10.1016\/j.intimp.2009.08.008_bib18","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.micpath.2007.06.001","article-title":"Naloxone, an opioid receptor antagonist, enhances induction of protective immunity against HSV-1 infection in BALB\/c mice","volume":"43","author":"Jamali","year":"2007","journal-title":"Microb Pathog"},{"key":"10.1016\/j.intimp.2009.08.008_bib19","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1038\/sj.bjp.0704577","article-title":"Naloxone prevents cell-mediated immune alterations in adult mice following repeated mild stress in the neonatal period","volume":"135","author":"Loizzo","year":"2002","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.intimp.2009.08.008_bib20","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0022-1759(02)00093-5","article-title":"Three-step purification of gp96 from human liver tumor tissues suitable for isolation of gp96-bound peptides","volume":"264","author":"Meng","year":"2002","journal-title":"J Immunol Methods"},{"key":"10.1016\/j.intimp.2009.08.008_bib21","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.cyto.2008.07.469","article-title":"Regulatory T cells in health and disease","volume":"43","author":"Piccirillo","year":"2008","journal-title":"Cytokine"},{"key":"10.1016\/j.intimp.2009.08.008_bib22","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/j.bbrc.2006.03.018","article-title":"Intra-tumoural regulatory T cells: a potential new target in cancer immunotherapy","volume":"343","author":"Needham","year":"2006","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.intimp.2009.08.008_bib23","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.coi.2004.01.010","article-title":"Immunoregulatory T cells in tumor immunity","volume":"16","author":"Terabe","year":"2004","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.intimp.2009.08.008_bib24","first-page":"3128","article-title":"Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor alpha) monoclonal antibody","volume":"59","author":"Onizuka","year":"1999","journal-title":"Cancer Res"},{"key":"10.1016\/j.intimp.2009.08.008_bib25","doi-asserted-by":"crossref","first-page":"5211","DOI":"10.4049\/jimmunol.163.10.5211","article-title":"Induction of tumor immunity by removing CD25+CD4+ T cells: a common basis between tumor immunity and autoimmunity","volume":"163","author":"Shimizu","year":"1999","journal-title":"J Immunol"},{"key":"10.1016\/j.intimp.2009.08.008_bib26","doi-asserted-by":"crossref","first-page":"3267","DOI":"10.1002\/1521-4141(200211)32:11<3267::AID-IMMU3267>3.0.CO;2-1","article-title":"Depletion of CD25+ regulatory cells uncovers immune responses to shared murine tumor rejection antigens","volume":"32","author":"Golgher","year":"2002","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.intimp.2009.08.008_bib27","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/0165-5728(93)90266-2","article-title":"Evidence for an opioid inhibitory effect on T cell proliferation","volume":"44","author":"Manfredi","year":"1993","journal-title":"J Neuroimmunol"},{"key":"10.1016\/j.intimp.2009.08.008_bib28","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/0165-5728(94)00189-U","article-title":"The beta-endorphin inhibition of mitogen-induced splenocytes proliferation is mediated by central and peripheral paracrine\/autocrine effects of the opioid","volume":"58","author":"Panerai","year":"1995","journal-title":"J Neuroimmunol"},{"key":"10.1016\/j.intimp.2009.08.008_bib29","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/S0165-5728(02)00268-0","article-title":"Increased splenocyte proliferative response and cytokine production in beta-endorphin-deficient mice","volume":"131","author":"Refojo","year":"2002","journal-title":"J Neuroimmunol"},{"key":"10.1016\/j.intimp.2009.08.008_bib30","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/S0376-8716(00)00181-2","article-title":"Opioids, opioid receptors, and the immune response","volume":"62","author":"McCarthy","year":"2001","journal-title":"Drug Alcohol Depend"},{"key":"10.1016\/j.intimp.2009.08.008_bib31","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1016\/S0022-3565(25)09571-0","article-title":"Antiproliferative effects of delta opioids on highly purified CD4+ and CD8+ murine T cells","volume":"273","author":"Shahabi","year":"1995","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.intimp.2009.08.008_bib32","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1046\/j.1365-2249.1998.00680.x","article-title":"Endogenous opioids modulate allograft rejection time in mice: possible relation with Th1\/Th2 cytokines","volume":"113","author":"Sacerdote","year":"1998","journal-title":"Clin Exp Immunol"}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576909002495?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576909002495?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,11]],"date-time":"2025-02-11T20:44:03Z","timestamp":1739306643000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576909002495"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,11]]},"references-count":32,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2009,11]]}},"alternative-id":["S1567576909002495"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2009.08.008","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2009,11]]}}}